Vodobatinib 是第三代具有口服活性的Bcr-Abl1酪氨酸激酶抑制剂，IC50=7 nM，对大多数 Bcr-Abl1 点突变体具有活性，但对 Bcr-Abl1T315I 无活性。它可用于研究慢性粒细胞白血病 (CML)。

Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.

1388803-90-4

C27H20ClN3O2

453.93

K-0706

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years